Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drug therapy for benign prostatic hyperplasia. Systematic overview].

R Berges1, K Höfner

  • 1Urologie, PAN-Klinik, Köln. r.berges@pan-klinik.org

Der Urologe. Ausg. A
|April 21, 2005
PubMed
Summary

5alpha-Reductase inhibitors and alpha(1)-receptor blockers effectively treat benign prostatic hyperplasia (BPH) symptoms. Proper patient selection and dosage are crucial for optimal outcomes in BPH management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Use of synthetic slings and mesh implants in the treatment of female stress urinary incontinence and prolapse : Statement of the Working Group on Urological Functional Diagnostics and Female Urology of the Academy of the German Society of Urology].

Der Urologe. Ausg. A·2019
Same author

[Fake News BPH - what is really true!]

Der Urologe. Ausg. A·2019
Same author

[Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].

Der Urologe. Ausg. A·2016
Same author

[Erratum to: Generation Y - problem or solution in daily clinical practice].

Der Urologe. Ausg. A·2016
Same author

[Terminology and Pathophysiology of Overactive Bladder (OAB)].

Aktuelle Urologie·2016
Same author

[Generation Y : Problem or solution in daily clinical practice].

Der Urologe. Ausg. A·2016

Area of Science:

  • Urology
  • Pharmacology

Context:

  • Benign Prostatic Hyperplasia (BPH) is a common condition in aging men.
  • Established treatments include 5alpha-Reductase inhibitors and alpha(1)-receptor blockers.

Purpose:

  • To outline optimal strategies for the symptomatic treatment of benign prostatic hyperplasia (BPH).
  • To guide patient selection and therapeutic approaches based on prostate volume and symptom severity.

Summary:

  • Maximum efficacy in BPH treatment depends on correct dosage and careful patient selection.
  • Alpha(1)-receptor blockers are suitable for monotherapy in patients with small prostates.
  • Combination therapy is beneficial for patients with large prostates.
  • Urological examination is essential to exclude prostatic obstruction before initiating drug therapy.
  • Patients should be informed about the Prostate Cancer Prevention Trial findings when using 5alpha-reductase inhibitors.

Impact:

  • Informed clinical decision-making for BPH management.
  • Improved patient outcomes through tailored treatment strategies.
  • Enhanced understanding of medication efficacy and patient selection criteria for BPH.

Related Experiment Videos